SVF
Insufficient· Insufficient EvidenceNarrative Review

Cardiac Repair and Mesenchymal Stem Cells: Exploring New Frontiers in Regenerative Medicine.

Nazir S., Maqbool T., Savas S.

Narrative Review on Cardiovascular Disease, Immune Modulation, published in Curr Cardiol Rev (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Cardiol Rev (2026)
Country
United Arab Emirates
Reported sample size
—
PMID
40760749
DOI
10.2174/011573403X376065250728094646

Abstract (original English)

Cardiovascular diseases, especially myocardial infarction, remain the prominent causes of death globally, necessitating the exploration of innovative therapeutic strategies. Medical and surgical available treatments mainly manage disease symptoms and prevent deterioration, but do not focus on the repair of lost cardiomyocytes. Mesenchymal stem cells (MSCs) have emerged as a promising tool for heart repair and regeneration after injury, as they possess unique properties, such as the potential for differentiation into cardiomyocytes and vascular endothelial cells, immunomodulation, the release of mediators, and paracrine effects. This review focuses on the latest understanding of MSC therapies for cardiac repair, specifically addressing their properties, mechanism of action, preclinical and clinical studies, problems and prospects, and future strategies. MSCs can be isolated from various tissues, including bone marrow and adipose tissue, each with its own advantages and disadvantages in cardiac repair. Many preclinical studies conducted concluded that MSCs could differentiate into cardiomyocytes. MSCs involve multiple factors that enhance angiogenesis, promote the survival of existing myocardium and cardiomyocytes, reduce fibrosis, modulate the immune response, activate existing cardiac stem cells, and facilitate tissue remodeling; all of these processes are crucial in myocardial

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

There is currently not enough data to draw conclusions about benefit or risk for this topic.

How we grade evidence
HumansMesenchymal Stem Cell TransplantationRegenerative MedicineMesenchymal Stem CellsMyocytes, CardiacMyocardial InfarctionRegenerationAnimalsCell Differentiation
Face & SkinSystemic / IVCardiovascular DiseaseImmune Modulation
View on PubMedDOI

Related research